Novo's $30 Billion Heart Drug Failure Puts the Inflammation Hypothesis on Trial

The inflammation hypothesis just took a $30 billion hit. Novo Nordisk's ziltivekimab, an experimental anti-inflammatory drug aimed at heart and kidney disease, failed its pivotal ZEUS phase 3 trial, wiping out $30 billion in market value in a single day. In more than 6,300 patients, the drug did lower inflammation markers — but that never translated into fewer heart attacks, strokes, or cardiovascular deaths. It's the kind of result that makes cardiology's...